Butalbital, Acetaminophen And Caffeine Capsule
NDC Package 51862-179-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is approaching its end of marketing date. An upcoming end of marketing date means the product has been delisted but will remain in the NDC database until the end of marketing date is reached. In most cases, the FDA advises firms to use the expiration date of the last lot produced as the end marketing date, reflecting the possibility that the product may still be available even after manufacturing has stopped.

Butalbital, Acetaminophen And Caffeine capsules is butalbital, acetaminophen and caffeine capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache.Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. This formulation utilizes a capsule delivery system. Marketed by Mayne Pharma, this product is identified by NDC 51862-179 and is authorized under FDA application ANDA089007.

Identification & Billing

NDC Package Code
51862-179-01
Package Description
100 CAPSULE in 1 BOTTLE, PLASTIC
Product Code
51862-179
11-Digit Billing Format
51862017901
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
100 EA
RxNorm Crosswalk
  • RxCUI: 238153 - butalbital 50 MG / acetaminophen 325 MG / caffeine 40 MG Oral Capsule
  • RxCUI: 238153 - acetaminophen 325 MG / butalbital 50 MG / caffeine 40 MG Oral Capsule
  • RxCUI: 238153 - APAP 325 MG / butalbital 50 MG / Caffeine 40 MG Oral Capsule

Clinical Specifications

Proprietary Name
Butalbital, Acetaminophen And Caffeine
Non-Proprietary Name
Butalbital, Acetaminophen And Caffeine
Substance Name
Acetaminophen; Butalbital; Caffeine
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Pharmacologic Class
Usage Information
Butalbital, acetaminophen and caffeine capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache.Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable.

Regulatory & Marketing

Labeler Name
Mayne Pharma
Product Type
Human Prescription Drug
FDA Application #
ANDA089007
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
04-16-2012
End Marketing Date
09-19-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51862-179-01 identifies a specific commercial package of 100 capsule in 1 bottle, plastic of Butalbital, Acetaminophen And Caffeine, a human prescription drug labeled by Mayne Pharma. This capsule is formulated for oral use and contains acetaminophen; butalbital; caffeine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Mayne Pharma on April 16, 2012.

How is this Mayne Pharma product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51862017901. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
51862-179-01
11-Digit CMS (5-4-2)
51862-0179-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.